Endocrinology · USMLE Step 1 and Step 2

Sulfonylureas song

Sulfonylureas - Mechanism & Hypoglycemia, as a song. Hear the short teaser here. The full song is on YouTube and Spotify.

Sulfonylureas

Full song on YouTube ↗Spotify ↗

Key points in this song10

Sulfonylureas (glipizide, glyburide, glimepiride) stimulate insulin secretion by closing ATP-sensitive K⁺ channels on pancreatic beta cells, causing membrane depolarization and calcium-mediated insulin release independent of blood glucose levels.
Because insulin release is glucose-independent, sulfonylureas are the oral antidiabetics most associated with hypoglycemia, especially in elderly patients or those with renal impairment.
Glyburide is contraindicated in renal insufficiency due to active metabolite accumulation; glipizide is preferred in chronic kidney disease because it is hepatically inactivated with no active renal metabolites.
Sulfonylureas cause weight gain due to increased insulin levels promoting lipogenesis and appetite stimulation, distinguishing them from metformin and GLP-1 agonists.
First-generation agents (tolbutamide, chlorpropamide) caused more drug interactions and side effects; chlorpropamide classically causes SIADH-like hyponatremia and disulfiram-like reactions with alcohol.
Sulfonylureas require functioning beta cells to work, making them ineffective in Type 1 diabetes and late-stage Type 2 diabetes with beta cell exhaustion.
The mechanism of action is the same target as ATP-sensitive K⁺ channel mutations seen in congenital hyperinsulinism (KATP channel gain-of-function mutations cause neonatal diabetes; loss-of-function causes hypoglycemia).
Sulfonylurea overdose or factitious hypoglycemia is identified by high insulin, high C-peptide, and low or undetectable blood glucose; C-peptide is elevated because endogenous proinsulin is cleaved (distinguishes it from exogenous insulin injection).
Treatment of sulfonylurea-induced hypoglycemia includes IV dextrose and octreotide, which suppresses insulin secretion by activating somatostatin receptors on beta cells.
Sulfonylureas are considered second-line agents after metformin in Type 2 diabetes management per ADA guidelines, with preference shifting toward SGLT-2 inhibitors or GLP-1 agonists in patients with cardiovascular disease or CKD.